Vyome Holdings (HIND) Deferred Taxes (2022 - 2025)

Vyome Holdings (HIND) posted quarterly Deferred Taxes of -$2000.0 for Q2 2025, up 50.0% quarter-over-quarter from -$4000.0 in Q1 2025.

Vyome Holdings (HIND) Deferred Taxes (2022 - 2025) Analysis & Trends

Vyome Holdings' Deferred Taxes history runs 4 years deep, the most recent figure standing at -$2000.0 for Q2 2025.

In Q2 2025, Deferred Taxes changed N/A year-over-year to -$2000.0; the TTM figure through Jun 2025 stood at -$5000.0 (down 116.67% YoY), while the FY2024 annual figure was $6000.0, down 78.57% from the prior year.
Deferred Taxes for Q2 2025 stood at -$2000.0, up from -$4000.0 in the prior quarter.
The five-year high for Deferred Taxes was $188000.0 in Q2 2022, with the low at -$180000.0 in Q3 2022.
The 4-year median for Deferred Taxes is $1500.0 (2023), against an average of $29300.0.
The sharpest annual moves came in 2024 and 2025: Deferred Taxes jumped 200.0% in 2024, then sank 500.0% in 2025.
Vyome Holdings' Deferred Taxes stood at $75000.0 in 2022, then sank by 64.0% to $27000.0 in 2023, then sank by 96.3% to $1000.0 in 2024, then slumped by 300.0% to -$2000.0 in 2025.
Business Quant data shows HIND's Deferred Taxes at -$2000.0 in Q2 2025, -$4000.0 in Q1 2025, and $1000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Vertex Pharmaceuticals	139.69 Bn	131.84 Bn	2.84 Bn	-69.70 Mn
2	Regeneron Pharmaceuticals	86.54 Bn	78.54 Bn	3.93 Bn	194.40 Mn
3	Argenx Se	65.27 Bn	60.09 Bn	1.37 Bn	-
4	Moderna	59.41 Bn	54.27 Bn	52.00 Mn	-
5	BeOne Medicines	42.12 Bn	37.02 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.80 Bn	28.49 Bn	992.69 Mn	2.66 Mn
7	BioNTech SE	28.07 Bn	9.68 Bn	668.28 Mn	-
8	Insmed	27.55 Bn	26.39 Bn	358.27 Mn	-
9	Royalty Pharma	27.28 Bn	26.44 Bn	-	-
10	Vyome Holdings	16.00 Mn	8.11 Mn	11,658.00	-

Download Data